Top

Published in:

Open Access 01-12-2019 | Kidney Cancer | Research article

Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma

Authors: Bo Fan, Wei Wang, Xianping Zhang, Min Sun, Xiaogang Wang, Zhiqi Chen, Wankai Liu, Qun Wang, Na Yu, Xiancheng Li

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

FBXO11, a member of the F-box protein family, regulates the cell-cycle by promoting the degradation of Bcl-6 and p53. This protein has been implicated in the progression of several cancers, including renal cell carcinoma (RCC). The aim of this study was to determine the prognostic role of FBXO11 in the clinical outcome of RCC patients.

Methods

FBXO11 mRNA expression was analysed in normal and RCC tissue microarrays of the Oncomine database. In addition, the in situ expression levels of stromal FBXO11 protein were assessed in primary RCC tissues from 227 patients (training and validation cohorts) using immunohistochemistry (IHC). Kaplan Meier and Cox regression analyses were used to determine the association between FBXO11 expression and cliniopathological factors. A nomogram was established using the significant prognostic factors to predict overall survival (OS) of RCC patients after one, three and 5 years.

Results

In the Oncomine database, FBXO11 mRNA levels were lower in normal tissues than in cancer tissues, including clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), hereditary ccRCC, non-hereditary ccRCC, VHL mutant ccRCC and VHL wild-type ccRCC. In addition, FBXO11 expression was also significantly higher in metastatic kidney cancer than in primary cancer. Immunohistochemical analysis reported that 57.3% (86 of 150) of the training cohort and 57.1% (44 of 77) of the validation cohort were scored as having high FBXO11 staining density. FBXO11 expression was significantly associated with Fuhrman grade (p = 0.003), UISS score (p = 0.021) and age (p = 0.048) in the training cohort. Furthermore, Kaplan-Meier survival analysis showed that higher FBXO11 levels, T stage, UISS scores and SSIGN score were associated with poor OS in ccRCC patients. Multivariate Cox analysis demonstrated that higher FBXO11 levels and higher UISS score were independent prognostic indicators for OS. Nomogram, calibration plots, AUC values and the C-index showed that the predictive accuracy of conventional prognostic models, including UISS score and SSIGN score, was improved when FBXO11 expression was added.

Conclusions

FBXO11 expression was closely related to RCC malignancy and poor prognosis, indicating its potential as a prognostic marker as well as a therapeutic target for RCC.

Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 2014;11:517–25. https://doi.org/10.1038/nrurol.2014.194.CrossRefPubMed

CJD W, Klaassen Z, Bhindi B, Ye XY, Chandrasekar T, Farrell AM, Goldberg H, Boorjian SA, Leibovich B, Kulkarni GS, Shah PS, Bjarnason GA, DYC H, Satkunasivam R, Finelli A. First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol. 2018;74:309–21. https://doi.org/10.1016/j.eururo.2018.03.036.CrossRef

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.CrossRefPubMed

Huang Q, Sun Y, Ma X, Gao Y, Li X, Niu Y, Zhang X, Chang C. Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma. Nat Commun. 2017;8(918). https://doi.org/10.1038/s41467-017-00701-6.

Grünwald V, Lin X, Kalanovic D, Simantov R. Early tumour shrinkage: a tool for the detection of early clinical activity in metastatic renal cell carcinoma. Eur Urol. 2016;70:1006–15. https://doi.org/10.1016/j.eururo.2016.05.010.CrossRefPubMed

Bhindi B, Thompson RH, Lohse CM, Mason RJ, Frank I, Costello BA, Potretzke AM, Hartman RP, Potretzke TA, Boorjian SA, Cheville JC, Leibovich BC. The probability of aggressive versus indolent histology based on renal tumor size: implications for surveillance and treatment. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.06.003.CrossRefPubMed

Gu L, Li H, Wang Z, Wang B, Huang Q, Lyu X, Shen D, Gao Y, Fan Y, Li X, Xie Y, Du S, Liu K, Tang L, Peng C, Ma X, Zhang X. A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy. Cancer Treat Rev. 2018;69:112–20. https://doi.org/10.1016/j.ctrv.2018.06.014.CrossRefPubMed

Zhang L, Wu B, Zha Z, Zhao H, Feng Y. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis. Cancer Manag Res. 2018;10:1687–703. https://doi.org/10.2147/CMAR.S166710.CrossRefPubMedPubMedCentral

Sejima T, Iwamoto H, Morizane S, Hinata N, Yao A, Isoyama T, Saito M, Takenaka A. The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma. Urol Oncol. 2013;31:1343–9. https://doi.org/10.1016/j.urolonc.2011.09.008.CrossRefPubMed

10.

Kroeger N, Zimmermann U, Burchardt M, Pantuck AJ. Prognostication in localised renal cell carcinoma. Lancet Oncol. 2015;16:603–4. https://doi.org/10.1016/S1470-2045(15)70227-5.CrossRefPubMed

11.

Díaz VM, de Herreros AG. F-box proteins: keeping the epithelial-to-mesenchymal transition (EMT) in check. Semin Cancer Biol. 2016;36:71–9. https://doi.org/10.1016/j.semcancer.2015.10.003.CrossRefPubMed

12.

Jin Y, Shenoy AK, Doernberg S, Chen H, Luo H, Shen H, Lin T, Tarrash M, Cai Q, Hu X, Fiske R, Chen T, Wu L, Mohammed KA, Rottiers V, Lee SS, Lu J. FBXO11 promotes ubiquitination of the Snail family of transcription factors in cancer progression and epidermal development. Cancer Lett. 2015;362:70–82. https://doi.org/10.1016/j.canlet.2015.03.037.CrossRefPubMedPubMedCentral

13.

Guan C, Lin F, Zhou M, Hong W, Fu L, Xu W, Liu D, Wan Y, Xu A. The role of VIT1/FBXO11 in the regulation of apoptosis and tyrosinase export from endoplasmic reticulum in cultured melanocytes. Int J Mol Med. 2010;26:57–65.PubMed

14.

Xue J, Chi Y, Chen Y, Huang S, Ye X, Niu J, Wang W, Pfeffer LM, Shao ZM, Wu ZH, Wu J. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Oncogene. 2016;35:448–58. https://doi.org/10.1038/onc.2015.96.CrossRefPubMed

15.

Zheng H, Shen M, Zha YL, Li W, Wei Y, Blanco MA, Ren G, Zhou T, Storz P, Wang HY, Kang Y. PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell. 2014;26:358–73. https://doi.org/10.1016/j.ccr.2014.07.022.CrossRefPubMedPubMedCentral

16.

Fan B, Zhang H, Jin H, Gai Y, Wang H, Zong H, Jin M, Yang H, Wan S, Zhu J, Xu S, Wang J, Yang D, Song X. Is overexpression of Ki-67 a prognostic biomarker of upper tract urinary carcinoma? A retrospective cohort study and meta-analysis. Cell Physiol Biochem. 2016;40:1613–25. https://doi.org/10.1159/000453211.CrossRefPubMed

17.

Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005;11:5730–9. https://doi.org/10.1158/1078-0432.CCR-04-2225.CrossRefPubMed

18.

Beroukhim R, Brunet JP, Di NA, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009;69:4674–81. https://doi.org/10.1158/0008-5472.CAN-09-0146.CrossRefPubMedPubMedCentral

19.

Le PIC, Sarangarajan R, Zhao Y, Stennett LS, Brown TL, Sheth P, Miki T, Boissy RE. ‘VIT1’, a novel gene associated with vitiligo. Pigment Cell Res. 2001;14:475–84.CrossRef

20.

Willems AR, Schwab M, Tyers M. A hitchhiker’s guide to the cullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta. 2004;1695:133–70. https://doi.org/10.1016/j.bbamcr.2004.09.027.CrossRefPubMed

21.

Jackson S, Xiong Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci. 2009;34:562–70. https://doi.org/10.1016/j.tibs.2009.07.002.CrossRefPubMedPubMedCentral

22.

Abbas T, Mueller AC, Shibata E, Keaton M, Rossi M, Dutta A. CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. Mol Cell. 2013;49:1147–58. https://doi.org/10.1016/j.molcel.2013.02.003.CrossRefPubMedPubMedCentral

23.

Rossi M, Duan S, Jeong YT, Horn M, Saraf A, Florens L, Washburn MP, Antebi A, Pagano M. Regulation of the CRL4(Cdt2) ubiquitin ligase and cell-cycle exit by the SCF (Fbxo11) ubiquitin ligase. Mol Cell. 2013;49:1159–66. https://doi.org/10.1016/j.molcel.2013.02.004.CrossRefPubMedPubMedCentral

24.

Abida WM, Nikolaev A, Zhao W, Zhang W, Gu W. FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J Biol Chem. 2007;282:1797–804. https://doi.org/10.1074/jbcM609001200.CrossRefPubMed

25.

Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8:438–49. https://doi.org/10.1038/nrc2396.CrossRefPubMedPubMedCentral

26.

Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di CPF, Chapuy B, Shipp M, Chiarle R, Pagano M. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012;481:90–3. https://doi.org/10.1038/nature10688.CrossRefPubMedPubMedCentral

27.

Schneider C, Kon N, Amadori L, Shen Q, Schwartz FH, Tischler B, Bossennec M, Dominguez-Sola D, Bhagat G, Gu W, Basso K, Dalla-Favera R. FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease. Blood. 2016;128:660–6. https://doi.org/10.1182/blood-2015-11-684357.CrossRefPubMed

28.

Sun C, Tao Y, Gao Y, Xia Y, Liu Y, Wang G, Gu Y. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT. Biomed Pharmacother. 2018;98:416–23. https://doi.org/10.1016/j.biopha.2017.12.088.CrossRefPubMed

29.

Ju UI, Park JW, Park HS, Kim SJ, Chun YS. FBXO11 represses cellular response to hypoxia by destabilizing hypoxia-inducible factor-1α mRNA. Biochem Biophys Res Commun. 2015;464:1008–15. https://doi.org/10.1016/j.bbrc.2015.07.037.CrossRefPubMed

30.

Yang CH, Pfeffer SR, Sims M, Yue J, Wang Y, Linga VG, Paulus E, Davidoff AM, Pfeffer LM. The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. J Biol Chem. 2015;290:6037–46. https://doi.org/10.1074/jbc.M114.632125.CrossRefPubMedPubMedCentral

31.

Hardisty-Hughes RE, Tateossian H, Morse SA, Romero MR, Middleton A, Tymowska-Lalanne Z, Hunter AJ, Cheeseman M, Brown SD. A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse. Hum Mol Genet. 2006;15:3273–9. https://doi.org/10.1093/hmg/ddl403.CrossRefPubMed

32.

Tateossian H, Hardisty-Hughes RE, Morse S, Romero MR, Hilton H, Dean C, Brown SD. Regulation of TGF-beta signalling by Fbxo11, the gene mutated in the Jeff otitis media mouse mutant. Pathogenetics. 2009;2:5. https://doi.org/10.1186/1755-8417-2-5.CrossRefPubMedPubMedCentral

33.

Tateossian H, Morse S, Simon MM, Dean CH, Brown SD. Interactions between the otitis media gene, Fbxo11, and p53 in the mouse embryonic lung. Dis Model Mech. 2015;8:1531–42. https://doi.org/10.1242/dmm.022426.CrossRefPubMedPubMedCentral

34.

Ma Y, Deng F, Li P, Chen G, Tao Y, Wang H. The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells. Biomed Pharmacother. 2018;101:648–55. https://doi.org/10.1016/j.biopha.2018.02.118.CrossRefPubMed

35.

Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–80. https://doi.org/10.1016/S1470-2045(14)71116-7.CrossRefPubMedPubMedCentral

36.

Shariat SF, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res. 2008;14:4400–7. https://doi.org/10.1158/1078-0432.CCR-07-4713.CrossRefPubMed

37.

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70. https://doi.org/10.1200/JCO.2007.12.9791.CrossRefPubMed

38.

Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, Ma ZL, Liu ZY. Development and validation of a Radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal Cancer. J Clin Oncol. 2016;34:2157–64. https://doi.org/10.1200/JCO.2015.65.9128.CrossRefPubMed

39.

Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC, Leibovich BC. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma. Eur Urol. 2014;66:929–35. https://doi.org/10.1016/j.eururo.2013.12.017.CrossRefPubMed

Title: Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma
Authors: Bo Fan
Wei Wang
Xianping Zhang
Min Sun
Xiaogang Wang
Zhiqi Chen
Wankai Liu
Qun Wang
Na Yu
Xiancheng Li
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5736-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas

The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data

Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes

Intra-arterial EmboCept S® and DC Bead® effectively inhibit tumor growth of colorectal rat liver metastases

IL1A polymorphisms is a risk factor for colorectal cancer in Chinese Han population: a case control study

Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer